BRCA1 and ovarian carcinoma: European Society for Medical Oncology and European Society of Gynecological Oncology (ESMO-ESGO) consensus conference recommendations on ovarian cancer published in 2019 recognize that poly-ADP ribose polymerase (PARP) inhibitors have greatest activity in patients with PV/LPV in BRCA genes, and thus testing for BRCA1/2 PV/LPV is recommended for all non-mucinous ovarian cancer [10].